Served with minimum fuss, American drugmaker Mallinckrodt’s second examinership in as many years was a side dish to the parallel Chapter 11 proceedings taking place in the United States. By the time the scheme put forward by examiner Michael McAteer to write down billions in debt and save the Irish-headquartered pharmaceutical plc from collapse was confirmed by Justice Michael Quinn in the High Court earlier this year, the heavy lifting had already been done in the Bankruptcy Court in Delaware.  On October 10, US Judge John Dorsey sanctioned a pre-pack rescue plan the troubled global pharma manufacturer had agreed with its…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €50.

Subscribe

Cancel at any time.

Are you already a member? .